Last updated: September 14, 2026
Alavert Allergy is an over-the-counter loratadine brand positioned around 24-hour, non-drowsy allergy relief. Its commercial opportunity is primarily in differentiated delivery systems, pediatric formats, sugar-free products, allergen-sensitive formulations and private-label manufacturing rather than in new active-ingredient exclusivity. Loratadine has long been genericized, and the principal commercial barriers are brand recognition, FDA compliance, formulation performance, retailer access and manufacturing scale.
What is Alavert Allergy and which active ingredient does it contain?
Alavert Allergy products contain loratadine, a second-generation antihistamine indicated for temporary relief of symptoms associated with allergic rhinitis, including sneezing, runny nose, itchy or watery eyes and itching of the nose or throat.
| Product characteristic |
Commercial profile |
| Active ingredient |
Loratadine |
| Common strength |
10 mg per dose |
| Regulatory category |
OTC antihistamine |
| Typical duration claim |
24 hours |
| Primary dosage forms |
Swallowed tablets and orally disintegrating or rapidly dissolving tablets |
| Primary users |
Adults and children meeting labeled age and dosing requirements |
| Therapeutic category |
Systemic H1 antihistamine |
| Prescription requirement |
None for standard OTC products |
| Biosimilar exposure |
None |
| Main competitive products |
Claritin, generic loratadine, store-brand loratadine and competing antihistamines |
Loratadine is regulated under the FDA’s OTC antihistamine monograph framework. The applicable monograph establishes permitted active ingredients, concentrations, labeling and conditions for marketing without an approved prescription drug application.[1]
What excipients are used in Alavert Allergy products?
The excipient composition depends on the specific Alavert dosage form and manufacturing source. Standard swallowed tablets generally use conventional tablet excipients, while orally disintegrating products require a more specialized system for rapid dispersion, acceptable mouthfeel and mechanical robustness.
Typical excipient classes relevant to Alavert-style loratadine products include:
| Excipient class |
Likely function in loratadine tablets |
| Diluent or filler |
Provides tablet mass and supports content uniformity |
| Binder |
Improves granule or tablet cohesion |
| Disintegrant |
Promotes breakup after swallowing |
| Superdisintegrant |
Enables rapid dispersion in orally disintegrating formats |
| Lubricant |
Reduces friction during compression and ejection |
| Glidant |
Improves powder flow |
| Sweetener |
Reduces bitterness and improves pediatric acceptability |
| Flavor |
Masks loratadine taste |
| Buffer or acidulant |
Controls taste, microenvironmental pH and dissolution |
| Coloring agent |
Supports product identification and brand differentiation |
| Compression aid |
Improves tablet strength and manufacturability |
For an orally disintegrating or rapidly dissolving product, a practical formulation may include mannitol or another mouthfeel-oriented filler, a superdisintegrant such as crospovidone or croscarmellose sodium, a low-level lubricant, flavor and an intense sweetener. Conventional tablets can use lactose, starch-based materials, microcrystalline cellulose, sodium starch glycolate, magnesium stearate or comparable excipients, depending on the manufacturer’s process.
The exact inactive-ingredient list should be taken from the current package labeling for the specific Alavert SKU. FDA’s Inactive Ingredient Database is useful for assessing prior route-of-administration and dosage-form precedent, but it does not establish that a particular excipient is approved for every strength or product configuration.[2]
Which excipient attributes matter most for loratadine tablets?
The highest-value excipient decisions concern dissolution, taste, manufacturability and consumer tolerability.
Taste masking
Loratadine has a bitter taste that becomes commercially important when the tablet dissolves in the mouth. ODT and chewable products require more than a standard sweetener. Effective systems may combine:
- High-intensity sweeteners such as sucralose, aspartame or acesulfame potassium.
- Polyols such as mannitol or sorbitol for bulk sweetness and cooling mouthfeel.
- Fruit or mint flavors.
- Polymer-based taste-masking coatings.
- Ion-exchange resins or lipid-based barriers where taste remains problematic.
A formulation relying only on a sweetener may produce a delayed bitter aftertaste. That can reduce repeat use, particularly in pediatric products.
Rapid disintegration
An orally disintegrating Alavert product needs sufficient capillary action and tablet porosity to disperse rapidly while retaining adequate resistance to chipping and abrasion. Crospovidone, croscarmellose sodium and sodium starch glycolate are common candidates. The preferred choice depends on compression force, particle size, moisture content and packaging.
Very high disintegrant levels can weaken tablets or increase friability. Very low levels can create a slow-dispersing product that fails the intended consumer experience.
Mouthfeel
Mannitol is commercially attractive for ODT products because it can provide a smooth, relatively cool mouthfeel and acceptable compressibility. Lactose and microcrystalline cellulose may support conventional tablets but can be less desirable in a fast-dissolving product if they create chalkiness or a prolonged residue.
Moisture control
Rapidly dissolving tablets may be sensitive to humidity. Moisture can cause premature softening, reduced disintegration performance, sticking during compression or degradation of moisture-sensitive flavor systems. Packaging may require high-barrier blisters, desiccant-containing bottles or both.
Lubrication
Magnesium stearate is widely used, but excessive lubrication can slow wetting and dissolution by creating hydrophobic surfaces around powder particles. The formulation and process must balance ejection performance against dissolution and dispersion.
What formulations are commercially attractive for Alavert Allergy?
Orally disintegrating tablets
ODTs are the strongest formulation opportunity because they support a clear consumer benefit: no water is required. The primary development targets are rapid dispersion, low tablet friability, taste masking and humidity resistance.
Potential commercial claims include:
- Dissolves in the mouth.
- No water needed.
- 24-hour allergy relief.
- Convenient use while traveling or outdoors.
The product must avoid implying faster systemic onset unless supported by appropriate evidence. Faster disintegration does not automatically establish faster clinical relief.
Chewable tablets
Chewables are relevant for children and consumers who have difficulty swallowing. They require stronger taste masking than swallowed tablets. Sugar-free versions can broaden use among consumers monitoring sugar intake, but polyol-heavy formulations can create gastrointestinal tolerability concerns at higher daily exposure.
Liquid formulations
A loratadine oral solution or syrup can target young children and consumers who cannot swallow tablets. Excipient strategy becomes more complex because the formulation must address:
- Solubility or suspension stability.
- Preservative effectiveness.
- Sweetener system.
- Viscosity.
- Flavor stability.
- Microbial control.
- Dose-measurement accuracy.
Liquid products can carry higher manufacturing and packaging costs than tablets. Unit-dose sachets, oral syringes or calibrated dosing cups can create differentiation, but each adds packaging and compliance requirements.
Fast-melt granules and stick packs
Single-dose granules or powder sachets could extend the brand into portable, water-free use. This format requires control of dusting, dose uniformity, moisture uptake and mouthfeel. It may be more suitable for adult convenience products than for young children unless the dosing system is carefully designed.
How should an excipient strategy address allergens and consumer restrictions?
Excipient selection can support label-based differentiation, but each claim must be substantiated and reflected accurately in the finished-product labeling.
Relevant commercial positions include:
| Consumer concern |
Excipient strategy |
| Sugar avoidance |
Use non-sugar sweeteners and suitable polyols |
| Gluten avoidance |
Select and qualify non-wheat-derived excipients and control supplier documentation |
| Dairy sensitivity |
Avoid lactose where commercially justified |
| Aspartame avoidance |
Use sucralose, acesulfame potassium or another suitable sweetener |
| Artificial-color avoidance |
Use no color or permitted natural-color alternatives |
| Vegan positioning |
Exclude gelatin and animal-derived processing aids |
| Pediatric use |
Reduce bitterness, control polyol load and use child-acceptable flavors |
| Diabetes-conscious use |
Use sugar-free claims only where formulation and labeling support them |
"Free-from" claims create supply-chain and testing obligations. The commercial value is highest when the claim addresses a recognized consumer concern without materially increasing tablet weight, moisture sensitivity or cost.
What FDA regulatory pathway applies to Alavert Allergy?
Standard loratadine OTC products can be marketed under the FDA’s OTC monograph system if they comply with the applicable active-ingredient, dosage, labeling and manufacturing requirements.[1]
Key FDA considerations include:
- The active ingredient and strength must fall within the permitted OTC conditions.
- The Drug Facts label must comply with FDA formatting and warning requirements.
- Inactive ingredients must be suitable for the dosage form and route.
- Manufacturing must comply with current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211.
- Pediatric dosing and age restrictions must match the applicable labeling.
- Any novel indication, materially different delivery system or unsupported performance claim may require a different regulatory analysis.
An excipient change can still be commercially significant even when it does not require a new approval pathway. It may affect stability, dissolution, content uniformity, bioequivalence, packaging, product complaints and postmarket quality.
What is the Orange Book status of Alavert Allergy?
Alavert Allergy is an OTC loratadine brand, and its commercial protection does not depend on an active Orange Book patent estate comparable to a currently marketed prescription drug.
The original loratadine composition and use patents have expired. The key historical patent is U.S. Patent No. 4,282,233, which covered loratadine-related compounds and was assigned to Schering Corporation.[3] Loratadine is now sold by multiple generic manufacturers and private-label suppliers.
| IP category |
Current commercial significance |
| Original loratadine compound patents |
Expired |
| Core loratadine formulation patents |
No meaningful barrier to ordinary generic tablets |
| Alavert brand trademarks |
Potentially relevant to branding and trade dress |
| New ODT formulation patents |
Potentially available if non-obvious and technically supported |
| Taste-masking patents |
Potentially available |
| Packaging patents |
Potentially available but usually narrow |
| Method-of-use patents |
Limited value for ordinary allergy indications |
| Biosimilar exclusivity |
Not applicable |
A new excipient combination could support patent protection only if it produces a defensible technical result, such as improved stability, faster dispersion, better taste performance or reduced friability. Merely substituting one routine excipient for another is unlikely to create a strong patent position.
When does loratadine lose exclusivity?
Loratadine lost core pharmaceutical exclusivity years ago. Generic and store-brand competition is established across tablets, chewables and liquid products.
Commercial exclusivity now comes from:
- Alavert brand recognition.
- Retailer placement.
- Package-size architecture.
- Product reviews and consumer repeat purchase.
- Proprietary formulation performance.
- Manufacturing cost.
- Trademark enforcement.
- Retailer or distributor agreements.
Paragraph IV challenges are not a central current risk for ordinary Alavert products because the underlying loratadine patents are expired and the products are generally marketed through OTC pathways rather than a current prescription NDA strategy. A new patented Alavert formulation could create a Paragraph IV risk if marketed through an NDA or otherwise listed in the Orange Book, but that would depend on the specific regulatory pathway and patent listing.
Which companies compete with Alavert Allergy?
The competitive market includes branded, generic and private-label products.
| Competitor group |
Examples |
Primary advantage |
| Branded loratadine |
Claritin and related products |
Brand recognition and broad distribution |
| Store brands |
Retailer-labeled loratadine |
Low price and shelf presence |
| Generic manufacturers |
Large-scale tablet suppliers |
Manufacturing cost and pharmacy distribution |
| Alternative antihistamines |
Cetirizine, levocetirizine, fexofenadine products |
Different perceived efficacy, onset or sedation profiles |
| Combination products |
Antihistamine-decongestant products |
Broader symptom coverage |
Alavert’s strongest defense is a clear format or value proposition. A conventional 10 mg loratadine tablet is difficult to distinguish from low-priced generics. An ODT, chewable, sugar-free or allergen-sensitive formulation has a stronger basis for premium pricing.
What commercial opportunities exist for Alavert excipients?
Premium ODT platform
A rapidly dissolving, taste-masked tablet could support premium pricing if it has strong mechanical integrity and reliable performance under humid storage. The most attractive technical package combines:
- Mannitol-based mouthfeel.
- Optimized superdisintegrant system.
- Low-bitterness flavor architecture.
- High-barrier packaging.
- Low friability.
- Stable 24-month shelf life.
Pediatric extension
A child-oriented chewable or liquid can expand household penetration. The principal opportunities are acceptable taste, accurate dosing, sugar-free positioning and simplified age-based labeling.
Private-label technology licensing
A validated loratadine ODT or chewable platform could be licensed to pharmacy chains, mass retailers, e-commerce brands and international OTC companies. The licensor’s value would come from the formulation package, scale-up data, supplier qualification and packaging configuration rather than from loratadine exclusivity.
Contract manufacturing
Manufacturers with direct compression, orally disintegrating tablet, stick-pack or liquid-filling capabilities can offer white-label loratadine products. Cost advantages may come from common excipient platforms shared across loratadine, cetirizine and fexofenadine products.
Global localization
Excipient and packaging choices can be adapted for local regulatory and consumer requirements. Opportunities include lactose-free products, gelatin-free products, lower-sugar formulations, multilingual labels and climate-specific packaging for hot or humid markets.
How strong is the patent estate for an Alavert excipient strategy?
The patent estate is weak for ordinary loratadine products and potentially moderate for a genuinely differentiated delivery platform.
| Strategy |
Patent strength |
Commercial assessment |
| Conventional 10 mg tablet |
Low |
Commodity competition |
| Generic ODT composition |
Low to moderate |
Patentability depends on unexpected performance |
| Proprietary taste-masking system |
Moderate |
Stronger if supported by comparative data |
| Humidity-resistant ODT package |
Moderate |
Protection may be divided between formulation and packaging |
| Pediatric chewable |
Low to moderate |
Brand and sensory performance may matter more than patents |
| Novel liquid stabilization system |
Moderate |
More technical barriers, but higher manufacturing cost |
| New allergy indication |
Low |
Ordinary symptom claims are crowded and regulated |
| Trademark and trade dress |
Moderate |
Commercially useful, especially in OTC retail |
The best patent candidates are formulation and manufacturing claims tied to measurable results. Examples include improved disintegration after accelerated humidity exposure, lower bitterness scores, reduced friability at a defined hardness, or improved loratadine dissolution without a corresponding increase in tablet mass.
What generic launch risks exist for Alavert Allergy?
Generic entry is already established. The relevant risk is continued price erosion and shelf displacement rather than a future first generic launch.
A new Alavert product would face:
- Retailer substitution with lower-priced loratadine.
- Private-label copycat formats.
- Rapid replication of common excipient systems.
- Limited consumer willingness to pay for conventional tablets.
- Seasonal demand concentration.
- Inventory risk after the spring allergy season.
- Packaging and claim-compliance costs.
- Consumer switching among loratadine, cetirizine and fexofenadine.
An excipient strategy should therefore be designed around a specific commercial metric: higher retail price, improved repeat purchase, lower manufacturing cost, superior stability or access to a new consumer segment.
Key Takeaways
- Alavert Allergy contains loratadine, a mature OTC antihistamine with no meaningful core-compound exclusivity.
- Excipient value is highest in ODT, chewable, liquid and sugar-free formats.
- Mannitol, superdisintegrants, taste-masking systems and moisture-resistant packaging are central development tools for differentiated products.
- Conventional loratadine tablets are commodity products and have limited premium potential.
- A new formulation may support patent protection only when it produces measurable, non-obvious technical benefits.
- The strongest commercial paths are premium ODT products, pediatric delivery systems, private-label licensing and contract manufacturing.
- Orange Book and Paragraph IV risks are limited for ordinary OTC loratadine products.
- Brand, retail access, package architecture and formulation performance are more important than legacy loratadine patents.
FAQs
Can Alavert Allergy be reformulated without changing the active ingredient?
Yes. A product can retain loratadine while changing fillers, disintegrants, sweeteners, flavors, lubricants, tablet structure or packaging. The finished product must continue to meet applicable FDA requirements and its labeled claims.
Which excipient is best for a loratadine orally disintegrating tablet?
Mannitol is a strong starting point for mouthfeel, but the optimal system depends on the selected superdisintegrant, compression process, flavor architecture, packaging and humidity target. No single excipient determines ODT performance.
Does lactose create a major commercial limitation for Alavert Allergy?
Lactose can limit use among consumers seeking dairy-free or lactose-free products, but its commercial importance depends on the specific SKU and labeling. A lactose-free formulation can create a useful differentiation point if the product has a credible consumer target.
Can an Alavert excipient combination receive a new patent?
Potentially. Patentability is more credible when the combination produces unexpected taste, stability, dissolution, friability or moisture-resistance results. Routine substitution of known tablet excipients is unlikely to provide strong protection.
Is a loratadine biosimilar relevant to Alavert Allergy?
No. Loratadine is a small-molecule drug, not a biologic. Competitive products are generics, private-label OTC products and alternative antihistamines, not biosimilars.
References
- U.S. Food and Drug Administration. (2024). Antihistamine drug products for over-the-counter human use, 21 C.F.R. § 341.
- U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
- U.S. Patent and Trademark Office. (1981). U.S. Patent No. 4,282,233: 11-(piperidinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine derivatives.
- U.S. Food and Drug Administration. (2024). Current good manufacturing practice, 21 C.F.R. Parts 210 and 211.
- U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
